GlassScriptPhysician profile
Brooks Zimmerman
NPI 1306845367
$4,427.77
in general payments reported to CMS, 2019-2025
35 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $106 · 2021: $560 · 2022: $956 · 2023: $737 · 2024: $709 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $591.10 | 2019-2023 | |
| Insulet Corporation | $551.02 | 2022-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $498.76 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $490.79 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $396.93 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $352.99 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $272.63 | 2021-2025 | |
| Abbvie INC. | $198.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $89.01 | 2019-2024 | |
| Amgen INC. | $73.81 | 2021-2024 | Prolia, Evenity, Otezla |
| Xeris Pharmaceuticals, INC. | $69.01 | 2021-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $67.40 | 2019-2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $59.01 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $54.69 | 2023-2024 | Xyosted, Nocdurna, Tlando |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.